Vantage logo

Ovid joins the rare epilepsy race

Ovid Therapeutics gets a mid-stage win in Dravet syndrome, but might have a hard time going up against Zogenix’s Fintepla.

Vantage logo

No buyout for Uniqure

But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.

Vantage logo

Myovant socks it to Orilissa

Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.